R. Kyle and S. Rajkumar, Multiple Myeloma, New England Journal of Medicine, vol.351, issue.18, pp.1860-1873, 2004.
DOI : 10.1056/NEJMra041875
URL : https://hal.archives-ouvertes.fr/hal-00557757

T. Witzig, M. Timm, D. Larson, T. Therneau, and P. Greipp, Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders, British Journal of Haematology, vol.97, issue.1, pp.131-137, 1999.
DOI : 10.1002/(SICI)1097-0320(19960615)26:2<113::AID-CYTO3>3.0.CO;2-H

M. Boccadoro, P. Gavarotti, and G. Fossati, Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy, British Journal of Haematology, vol.70, issue.4, pp.689-696, 1984.
DOI : 10.1016/0002-9343(78)90522-3

P. Greipp, J. Lust, O. Fallon, and W. , Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma, Blood, vol.81, pp.3382-3387, 1993.

F. Cremer, J. Bila, and I. Buck, Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics, Genes, Chromosomes and Cancer, vol.40, issue.2, pp.194-203, 2005.
DOI : 10.1002/gcc.20231

R. Fonseca, B. Barlogie, and R. Bataille, Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report, Cancer Research, vol.64, issue.4, pp.1546-1558, 2004.
DOI : 10.1158/0008-5472.CAN-03-2876

P. Andrews, E. Knatko, W. Moore, and J. Swedlow, Mitotic mechanics: the auroras come into view, Current Opinion in Cell Biology, vol.15, issue.6, pp.672-683, 2003.
DOI : 10.1016/j.ceb.2003.10.013

S. Dutertre, S. Descamps, and C. Prigent, On the role of aurora-A in centrosome function, Oncogene, vol.21, issue.40, pp.6175-6183, 2002.
DOI : 10.1038/sj.onc.1205775
URL : https://hal.archives-ouvertes.fr/inserm-00966247

N. Keen and S. Taylor, Aurora-kinase inhibitors as anticancer agents, Nature Reviews Cancer, vol.64, issue.12, pp.927-936, 2004.
DOI : 10.1038/sj.onc.1207593

J. Fu, M. Bian, Q. Jiang, and C. Zhang, Roles of Aurora Kinases in Mitosis and Tumorigenesis, Molecular Cancer Research, vol.5, issue.1, pp.1-10, 2007.
DOI : 10.1158/1541-7786.MCR-06-0208

M. Carmena and W. Earnshaw, The cellular geography of aurora kinases, Nature Reviews Molecular Cell Biology, vol.4, issue.11, pp.842-854, 2003.
DOI : 10.1038/nrm1245

J. Bischoff, L. Anderson, and Y. Zhu, A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers, The EMBO Journal, vol.17, issue.11, pp.3052-3065, 1998.
DOI : 10.1093/emboj/17.11.3052

Y. Nadler, R. Camp, and C. Schwartz, Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer, Clinical Cancer Research, vol.14, issue.14, pp.4455-4462, 2008.
DOI : 10.1158/1078-0432.CCR-07-5268

R. Giet, C. Petretti, and C. Prigent, Aurora kinases, aneuploidy and cancer, a coincidence or a real link?, Trends in Cell Biology, vol.15, issue.5, pp.241-250, 2005.
DOI : 10.1016/j.tcb.2005.03.004
URL : https://hal.archives-ouvertes.fr/inserm-00966568

S. Kimmins, C. Crosio, and N. Kotaja, Differential Functions of the Aurora-B and Aurora-C Kinases in Mammalian Spermatogenesis, Molecular Endocrinology, vol.21, issue.3, pp.726-739, 2007.
DOI : 10.1210/me.2006-0332

P. Andrews, Aurora kinases: shining lights on the therapeutic horizon?, Oncogene, vol.64, issue.32, pp.5005-5015, 2005.
DOI : 10.1038/sj.onc.1208153

D. Glover, M. Leibowitz, D. Mclean, and H. Parry, Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles, Cell, vol.81, issue.1, pp.95-105, 1995.
DOI : 10.1016/0092-8674(95)90374-7

R. Tyler, N. Shpiro, R. Marquez, and P. Eyers, VX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells, Cell Cycle, vol.6, issue.22, pp.2846-2854, 2007.
DOI : 10.4161/cc.6.22.4940

C. Ditchfield, V. Johnson, and A. Tighe, Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores, The Journal of Cell Biology, vol.114, issue.2, pp.267-280, 2003.
DOI : 10.1038/2496

S. Hauf, R. Cole, and S. Laterra, The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore???microtubule attachment and in maintaining the spindle assembly checkpoint, The Journal of Cell Biology, vol.114, issue.21, pp.281-294, 2003.
DOI : 10.1073/pnas.96.20.11335

F. Girdler, K. Gascoigne, and P. Eyers, Validating Aurora B as an anti-cancer drug target, Journal of Cell Science, vol.119, issue.17, pp.3664-3675, 2006.
DOI : 10.1242/jcs.03145

R. Evans, C. Naber, and T. Steffler, Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells, Leukemia & Lymphoma, vol.93, issue.3, pp.559-569, 2008.
DOI : 10.1038/ncb1309

R. Evans, C. Naber, and T. Steffler, The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma, British Journal of Haematology, vol.24, issue.18, pp.295-302, 2008.
DOI : 10.1182/blood-2007-02-073700

Y. Shi, T. Reiman, and W. Li, Targeting aurora kinases as therapy in multiple myeloma, Blood, vol.109, issue.9, pp.3915-3921, 2007.
DOI : 10.1182/blood-2006-07-037671

P. Greipp, S. Miguel, J. Durie, and B. , International Staging System for Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.15, pp.3412-3420, 2005.
DOI : 10.1200/JCO.2005.04.242

B. Durie, Staging and cinetics of Multiple Myeloma, Semin.Oncol, vol.13, pp.300-309, 1986.

J. Blade, D. Samson, and D. Reece, CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH-DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION, British Journal of Haematology, vol.88, issue.(Suppl. 2), pp.1115-1123, 1998.
DOI : 10.1046/j.1365-2141.1998.00930.x

H. Goldschmidt, P. Sonneveld, and F. Cremer, Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients, Annals of Hematology, vol.82, issue.10, pp.654-659, 2003.
DOI : 10.1007/s00277-003-0685-2

B. Barlogie, G. Tricot, and E. Rasmussen, Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies, Blood, vol.107, issue.7, pp.2633-2638, 2006.
DOI : 10.1182/blood-2005-10-4084

K. Mahtouk, D. Hose, and P. Raynaud, Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma, Blood, vol.109, issue.11, pp.4914-4923, 2007.
DOI : 10.1182/blood-2006-08-043232
URL : https://hal.archives-ouvertes.fr/inserm-00136105

J. Moreaux, F. Cremer, and T. Reme, The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, pp.1021-1030, 2005.
DOI : 10.1182/blood-2004-11-4512
URL : https://hal.archives-ouvertes.fr/inserm-00129406

X. Zhang, J. Gaillard, and N. Robillard, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

Z. Gu, D. Vos, J. Rebouissou, and C. , Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-197, 2000.
DOI : 10.1038/sj.leu.2401632

C. Rebouissou, J. Wijdenes, and P. Autissier, A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma, Blood, vol.91, pp.4727-4737, 1998.

K. Tarte, D. Vos, J. Thykjaer, and T. , Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts, Blood, vol.100, pp.1113-1122, 2002.

J. Corre, K. Mahtouk, and M. Attal, Bone marrow mesenchymal stem cells are abnormal in multiple myeloma, Leukemia, vol.63, pp.1079-1088, 2007.
DOI : 10.1038/sj.leu.2404621
URL : https://hal.archives-ouvertes.fr/inserm-00270565

D. Hose, J. Rossi, and C. Ittrich, A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival, ASH Annual Meeting Abstracts, vol.104, p.73, 2004.

S. Wuilleme, N. Robillard, and L. Lode, Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma, Leukemia, vol.19, issue.2, pp.275-278, 2005.
DOI : 10.1038/sj.leu.2403586

K. Mahtouk, D. Hose, and T. Reme, Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells, Oncogene, vol.83, issue.21, pp.3512-3524, 2005.
DOI : 10.1038/sj.onc.1208536
URL : https://hal.archives-ouvertes.fr/inserm-00130206

D. Vos, J. Couderc, G. Tarte, and K. , Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, issue.3, pp.771-780, 2001.
DOI : 10.1182/blood.V98.3.771

D. Vos, J. , J. M. Tarte, K. Jasmin, C. Klein et al., JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells, British Journal of Haematology, vol.83, issue.4, pp.823-828, 2000.
DOI : 10.1073/pnas.94.13.6764

T. Ro, R. Holt, and A. Brenne, Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells, Oncogene, vol.23, pp.3024-3032, 2004.

M. Jourdan, M. Ferlin, and E. Legouffe, The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells, British Journal of Haematology, vol.83, issue.4, pp.637-646, 1998.
DOI : 10.1046/j.1365-2141.1996.d01-1811.x

Z. Wu, R. Irizarry, R. Gentleman, F. Martinez-murillo, and F. Spencer, A Model-Based Background Adjustment for Oligonucleotide Expression Arrays, Journal of the American Statistical Association, vol.99, issue.468, pp.909-917, 2004.
DOI : 10.1198/016214504000000683

J. Taylor, R. Tibshirani, and B. Efron, The 'miss rate' for the analysis of gene expression data, Biostatistics, vol.6, issue.1, pp.111-117, 2005.
DOI : 10.1093/biostatistics/kxh021

G. Smyth, Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments, Statistical Applications in Genetics and Molecular Biology, vol.3, issue.1, p.3, 2004.
DOI : 10.2202/1544-6115.1027

Y. Benjamini and Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing, Journal of the Royal Statistical Society.Series B, vol.57, pp.289-300, 1995.